Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Immunotherapies in Lung Cancer, Part 2: Dr. Brahmer on Ipilumumab, Anti-PD1, Anticancer Viruses, and Talactoferrin
Author
Howard (Jack) West, MD

Here's the second presentation from our program on "Immunotherapies for Lung Cancer: Can We Deliver on the Promise?".  Our first part was by Dr. Ramaswamy Govindan from Washington University in St. Louis; he was followed by Dr. Julie Brahmer, from Johns Hopkins University, who covered a wide range of immunotherapy concepts: the anti-CTLA4 antibody ipilimumab, or Yervoy; the exciting new approach of anti-PD1 therapy as was more fully presented at ASCO, new work on anticancer vaccine approaches, and discussion of talactoferrin and the past and ongoing trials with it.  

Below you'll find the audio and video versions of the podcast, along with transcript and figures.

Brahmer Immunotherapies for LC Part 2 Audio Podcast

Brahmer Immunotherapies for LC Part 2 Transcript

Brahmer Immunotherapies in LC Part 2 Figs

We'll close out this program with the question and answer session that followed the two presentations.  Look for that soon.

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on